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OPEN
ORIGINAL ARTICLE
Lentivirus-induced ‘Smart’ dendritic cells: Pharmacodynamics
and GMP-compliant production for immunotherapy against
TRP2-positive melanoma
BS Sundarasetty1,10, L Chan2, D Darling2, G Giunti2, F Farzaneh2, F Schenck3, S Naundorf4, K Kuehlcke4, E Ruggiero5, M Schmidt5,
C von Kalle5, M Rothe6,10, DSB Hoon7, L Gerasch1,10, C Figueiredo8,10, U Koehl9,10, R Blasczyk8,10, R Gutzmer3,11 and R Stripecke1,10,11
Monocyte-derived conventional dendritic cells (ConvDCs) loaded with melanoma antigens showed modest responses in clinical trials.
Efﬁcacy studies were hampered by difﬁculties in ConvDC manufacturing and low potency. Overcoming these issues, we demonstrated
higher potency of lentiviral vector (LV)-programmed DCs. Monocytes were directly induced to self-differentiate into DCs (SmartDC-
TRP2) upon transduction with a tricistronic LV encoding for cytokines (granulocyte macrophage colony stimulating factor (GM-CSF)
and interleukin-4 (IL-4)) and a melanoma antigen (tyrosinase-related protein 2 (TRP2)). Here, SmartDC-TRP2 generated with monocytes
from ﬁve advanced melanoma patients were tested in autologous DC:T cell stimulation assays, validating the activation of functional
TRP2-speciﬁc cytotoxic T lymphocytes (CTLs) for all patients. We described methods compliant to good manufacturing practices (GMP)
to produce LV and SmartDC-TRP2. Feasibility of monocyte transduction in a bag system and cryopreservation following a 24-h
standard operating procedure were achieved. After thawing, 50% of the initial monocyte input was recovered and SmartDC-TRP2 self-
differentiated in vitro, showing uniform expression of DC markers, detectable LV copies and a polyclonal LV integration pattern not
biased to oncogenic loci. GMP-grade SmartDC-TRP2 expanded TRP2-speciﬁc autologous CTLs in vitro. These results demonstrated a
simpler GMP-compliant method of manufacturing an effective individualized DC vaccine. Such DC vaccine, when in combination with
checkpoint inhibition therapies, might provide higher speciﬁcity against melanoma.
Gene Therapy (2015) 22, 707–720; doi:10.1038/gt.2015.43
INTRODUCTION
Melanoma has rising incidence rates higher than any other
malignancy. The ﬁeld of treatment of metastatic melanoma is
rapidly evolving at the moment with several targeted strategies in
development.1,2 Recent developments have considerably changed
the standard of care for metastatic melanoma, such as for patients
with metastatic melanomas harboring speciﬁc genetic mutations,
that is, B-RAFV600 mutations. Trials with agents targeting these
mutations such as Vemurafenib and Dabrafenib have shown
objective responses and causing tumor regression in more than
50% of melanoma patients.3,4 Despite these improvements,
clinical responses are short term and tumor resistance to these
molecular-targeted drugs is a common event. Therefore, other
treatment options that provide long-lasting tumor control are
warranted.
Melanoma is an immunogenic tumor, and thus a variety of
immunotherapies have been explored to drive immune responses
that are capable of long-term tumor control. Ipilimumab was
recently approved as the ﬁrst immune checkpoint inhibitor for the
treatment of metastatic melanoma. Ipilimumab binds to CTLA-4,
and therefore blocks a negative feedback mechanism that
physiologically limits T-cell activation. By blocking this pathway,
T cells stay activated, which results in a sustained and often long-
term anti-tumor immune response in ~ 20% of patients.5 The use
of this agent in the adjuvant setting is currently investigated in
a clinical placebo-controlled trial in stage III melanoma patients
after complete resection of regional lymph node (LN) metastases.
Unfortunately, strong off-target autoimmune side effects are
regularly observed during ipilimumab therapy.6 PD-1 has been
explored as another immune checkpoint in melanoma, and two
PD-1 blocking antibodies (pembrolizumab and nivolumab) have
been recently registered by the Food and Drug Administration for
the treatment of ipilimumab-refractory metastatic melanoma
patients.7–9 In addition, adoptive T-cell therapies are being
developed in clinical trials with T-cell receptors and chimeric
antigen receptors against a variety of melanoma-associated
antigens and surface molecules expressed in melanoma,
respectively.10 Although immune responses generated by these
engineered T cells are likely to be fast and potent, issues regarding
tumor speciﬁcity and toxicity can lead to therapeutic risks.
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On the other hand, numerous clinical trials have been carried
out assessing the ability of adaptive immunotherapy using ex vivo
generated conventional dendritic cells (ConvDCs) in the treatment
of melanoma. DC vaccines are well tolerated and no toxicity was
reported. Clinical trials with DC vaccines loaded with peptides
demonstrated complete responses in 3%, partial response in 6%
and stable disease in 21% of the patients tested.11 However, DC
clinical trials were compromised by several limitations in their
production methods: high costs, poor consistency, and low
viability of the ex vivo generated DCs loaded externally with
antigens.12 Although monocyte-derived DCs can be routinely
produced ex vivo in the presence of recombinant cytokines and
maturation factors, their migration from the immunization sites to
lymph nodes was limited,13 making this a major weakness in past
DC vaccination studies. Moreover, major histocompatibility com-
plex class I restricted peptide loading onto DC vaccines may be
insufﬁcient in generating broad immunological responses for
signiﬁcant clinical beneﬁts.14,15 In light of these reports, several
clinical trials have been engaged in loading DCs with full-length
melanoma-associated antigens,16 co-culturing DCs with tumor
lysates and mRNA transfection into the DCs for an optimal antigen
delivery.17
Interestingly, DCs transfected with in vitro transcribed mRNAs
have shown that the DC therapies have been feasible, safe and
induce melanoma-speciﬁc immunological responses. DCs trans-
fected with a mixture of RNAs encoding for stimulatory ligands
and melanoma-associated antigens led to 30% overall survival
rates in advanced pretreated unresectable melanoma patients
(stage IIIC or IV) in the absence of additional melanoma
treatments.18 Recent phase I clinical trial results obtained from a
single-arm, small patient study with a number of different mRNA
modiﬁed DC therapies (including combination with interferon-α-
2b (IFN-α-2b) adjuvant therapy) following the resection of
melanoma metastases resulted in 2 and 4 year overall survival
rates of 93% and 70%, respectively.19 In this trial, overall survival
was improved in the absence of a signiﬁcant improvement in
progression-free survival and therefore, encouraging, but no
deﬁnitive conclusions could be drawn. Overall, mRNA delivery
systems suffered from the instability of gene expression in
electroporated DCs (that might be not highly viable in vivo).
Moreover, DC vaccines transfected with mRNAs were less effective
in animal models than more persistent gene delivery systems such
as lentiviral vector (LV)-transduced DCs.21
Thus, clinical trials showing genetically modiﬁed DCs by various
viral vectors (such as fowlpox, vaccinia and adenovirus vectors)
expressing melanoma antigens were reported.20 However, these
vector systems had poor gene delivery efﬁciency, were cytotoxic
to DCs or stimulated T cells responses against co-expressed viral
proteins. Thus, in recent years, development of LVs has boomed
for gene transfer and vaccination studies as they can infect non-
proliferating cells, have low immunogenicity, can carry large
amounts of transgenic cargo (up to 7 Kb) and lead to persistent
transgene expression.22 LV technologies have been shown safe in
animal models and clinical trials for cancer immunotherapy using
T cells engineered with chimeric antigen receptor,23 gene therapy
of adrenoleukodistrophy24 and Wiskott Aldrich Syndrome.25
We have developed an innovative method for bio-engineering
DC by genetic reprogramming of DC precursors.26 LV gene
co-transfer of granulocyte macrophage colony stimulating
factor (GM-CSF) and interleukin (IL)-4 into hematopoietic pre-
cursors generated ‘Self-differentiated Myeloid-derived Antigen-
presenting-cells Reactive against Tumors-DC’ (‘SmartDC’).27,28 We
showed that bone marrow precursor cells obtained from immune
competent C57BL/6 mice or human CD14+ monocytes transduced
overnight with combinations of LVs co-expressing GM-CSF/IL-4
and a melanoma self-antigen (tyrosinase-related protein 2, TRP2)
could be used directly after transduction as vaccines applied
subcutaneously.27,29 The innovation of this approach was that the
injected cells engrafted, were highly viable and self-differentiated
effectively into DC in situ. Histological and optical imaging analyses
showed that SmartDC-TRP2 effectively migrated from the injection
site to local draining lymph nodes of C57BL/6 mice, where they
persisted for a few weeks, resulting into dramatic expansion of T cells
and anti-melanoma responses.26,29
We therefore advanced the SmartDC concept for translation into
clinical trials. In previous work, we reported a tricisitronic LV design
for combined co-expression of human or mouse GM-CSF, IL-4 and
TRP2 genes.27 Potency of mouse SmartDC-TRP2 was shown in the
homologous melanoma mouse model, whereas high viability of the
cryopreserved human SmartDC-TRP2 product was conﬁrmed in a
xenogeneic mouse model by optical bioluminescence analyses.27
We also showed proof-of-principle for a large-scale method of
human SmartDC-TRP2 generation.27 Here, we addressed key
additional requirements for clinical development of SmartDC-
TRP2. We demonstrate that T cells obtained from ﬁve advanced
melanoma patients attained TRP2-speciﬁc functional cytotoxic T
lymphocyte (CTL) responses after in vitro expansion with auto-
logous SmartDC-TRP2. We also show proof-of-concept for good
manufacturing practice (GMP)-compliant manufacturing and cryo-
preservation of SmartDC-TRP2, resulting into a thawed product with
the expected quality control speciﬁcation. The results obtained
herein pave way for the future clinical trials toward immunotherapy
of malignant melanoma patients with personalized SmartDC-TRP2
vaccines for adaptive melanoma-speciﬁc responses that might be
eventually combined with checkpoint inhibitors in order to provide
higher speciﬁcity against melanoma.
Figure 1. Pre-clinical validation of SmartDC-TRP2 in melanoma patients (n= 5). Human SmartDC-TRP2 generated from CD14+ monocytes from
melanoma patients show DC immunophenotye and are potential stimulators of T cells. CD14+ monocytes were isolated from PBMNCs of
melanoma patients, preconditioned with cytokines for 8 h and transduced with 2.5 μg p24 equivalents of LV-G242T for 16 h. Post transduction,
cells were washed and cultured for 7 days in medium without cytokines. (a) Tricistronic LV used for generating the SmartDC-TRP2 showing the
transgenes and 2 A elements. (b) Representative example of immunophenotypic analyses performed on day 7 SmartDC and SmartDC-TRP2.
Filled and unﬁlled histograms indicate FACS analyses with isotype control or relevant mAbs; numbers indicate percentages of positive cells.
(c) Immunophenotypic analyses of SmartDC-TRP2 generated from ﬁve independent melanoma patients. Bar graphs indicate percentage
positive cells. (d) Secreted cytokines in supernatants of SmartDC and SmartDC-TRP2 analyzed at day 7. White bars indicate GM-CSF and black
bars indicate IL-4. (e) Baseline TRP2 reactivity analyzed by quantifying the CD8+ T cells reactive against TRP2 tetramers: TRP2180-188 and
TRP2360-368 in ﬁve different melanoma patients used in the study. An irrelevant tetramer was used as negative control. (f) SmartDC, SmartDC/pep
or SmartDC-TRP2 were used in stimulation of autologous CD8+ T cells from the respective melanoma patients. Relative fold expansion of
T cells per group determined with trypan blue exclusion staining (relative to T-cell input). Line graph indicate the average values of
independent experiments and error bars indicate mean± s.e.m. *Po0.05. (g) IFN-γ ELISPOT analyses after two stimulations. 30 000 CD8+
T cells were co-cultured in the presence of KA2 cells or KA2 cells endogenously expressing TRP2 (KA2/TRP2) on IFN-γ coated ELISPOT plate.
T cells without any were used as controls. Average number of spots from duplicate wells was quantiﬁed. Histograms represent average
number of spots from pooled microculture wells (n= 3) per experimental condition. Bar graphs indicate average values of experiments
performed and error bars indicate mean± s.e.m. ***Po0.001 and **Po0.01. (h) Analyses of TRP2-speciﬁcity by tetramer analyses. Dots
indicate the frequencies of non-speciﬁc (control tetramer, circles), TRP2180-188 (squares) and TRP2360-368 (triangles) reactive CD8
+ T cells after
three cycles of stimulation with SmartDC, SmartDC/pep or SmartDC-TRP2. Results for three melanoma patients are shown.
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RESULTS
Generation and potency testing of SmartDC-TRP2 from melanoma
patients
The tricistronic LV-G242T (Figure 1a) co-expressing GM-CSF, IL-4 and
TRP2 interspaced with 2A elements was used to transduce CD14+
monocytes isolated from ﬁve melanoma patients. As a control group,
we included transduction of monocytes with LV-G24 vector for
production of ‘empty’ SmartDC (that is, not expressing the antigen).
The immunophenotypes of SmartDC-TRP2 and SmartDC 7 days after
transduction and in vitro culture were comparable for all patients
(Figure 1b, representative data). SmartDC-TRP2 productions resulted in
cells with low frequencies of the monocytic marker CD14 and high
frequencies of cells expressing the DC markers CD80, CCR2, CD209,
CD86 and HLA-DR (Figure 1c). Cell supernatants were collected on day
7 of culture for detection of transgenic GM-CSF and IL-4 cytokines
(Figure 1d). As CTLs reactive against TRP2 were previously identiﬁed in
tumors of melanoma patients,30 we therefore analyzed the peripheral
blood samples of melanoma patients in our study for the presence of
baseline TRP2-speciﬁc CTLs by tetramer analyses of TRP2180-188 and
TRP2360-368 HLA-A*02:01-restricted epitopes (Figure 1e). Staining with
tetramers binding to an irrelevant epitope was run as negative control.
Three of the melanoma patients showed low tetramer reactivity
against TRP2180-188 (o0.1% tetramer positive), whereas two patients
showed 1.3 and 1.8% CTL reactivity against TRP2180-188 (Figure 1e).
Tetramer reactivity against TRP2360-368 was lower, with CTL frequency
in average 0.2% (Figure 1e). In order to evaluate the in vitro activation
of autologous CTLs, ‘empty’ SmartDC, SmartDC/pep or SmartDC-TRP2
were co-cultured with CD8+ T cells for up to three rounds of
stimulation (Figure 1f). SmartDC-TRP2 stimulated the highest expan-
sion of CTLs after three rounds of stimulations and was signiﬁcantly
higher than SmartDC (28 fold vs 10 fold; Po0.05, relative to the T cell
input). SmartDC/pep induced slightly lower T cell expansion (21 fold)
compared to SmartDC-TRP2 (Figure 1f, Table 1). The expanded CTLs
were subsequently seeded on IFN-γ coated plates overnight with
target KA2 ‘empty’ cells or KA2 cells expressing full-length TRP2 (KA2/
TRP2). CTLs harvested after two rounds of stimulations with SmartDC-
TRP2 or SmartDC/pep showed signiﬁcantly higher reactivity against
KA2/TRP2 than CTLs expanded with SmartDC (3.5-fold; **Po0.01 and
4-fold; ***Po0.001, respectively; Figure 1g). In vitro expanded CTLs
were analyzed for the speciﬁcity against TRP2 epitopes by tetramer
analyses. Overall, a modest reactivity against TRP2180-188 was observed
for all CTL groups (Figure 1h). A trend for higher CTL reactivity against
TRP2360-368 was observed after expansion of T cells with SmartDC/pep
or with SmartDC-TRP2 than with ‘empty’ SmartDC (Figure 1h, Table 1).
Nevertheless, we could not establish a ﬁrm correlation between the
frequencies of TRP2-reactive CTLs at baseline for each patient detected
by tetramers and after in vitro expansion. It is possible that CTLs
reacting against other epitopes in TRP2 may be preferentially
expanded. In summary, comparing the effects of SmartDC-TRP2
(loaded with TRP2 endogenously) or SmartDC/pep (loaded with
antigens on the cell surface) versus ‘empty’ SmartDC for the different
analyses, the IFN-γ ELISPOT assay showed superior consistency for
quantiﬁcation of anti-TRP2-speciﬁc reactivity than analyses of T-cell
expansion or tetramer reactivity (Table 1).
CTLs expanded with SmartDC-TRP2 lyse TRP2-positive cells in vitro
We developed an assay to evaluate the potency of ex vivo expanded
TRP2-reactive CTLs regarding their capacity to speciﬁcally lyse HLA-
A*02:01-positive targets expressing TRP2 (Figure 2a). KA2, KA2/TRP2
and FEMX-I (a TRP2-positive human malignant melanoma cell line
originating from a lymph node metastasis) cells were used as targets
(Figure 2b). All cell lines, including FEMX-1, were uniformly labeled
with CFSE (Figure 2c). Upon exposure to the CTLs, cell lysis could be
followed by ﬂow cytometry as decreased frequencies of CD8− /CFSE-
labeled viable cells (Figure 2c). At various effector to target ratios (E:T
ratios), only 10–40% of the KA2 target cells (exposed to CTLs expanded
with all the three types of DCs) were lysed (Figure 2d). When KA2/TRP2
were used as targets, signiﬁcantly higher lysis was produced by CTLs
expanded with SmartDC-TRP2 and used at higher E:T ratios (9:1 and
27:1, Figure 2e) than CTLs expanded with SmartDC. When FEMX-I cells
were used as targets, the cytotoxicity caused by CTLs expanded with
SmartDC-TRP2 was signiﬁcantly higher for all E:T ratios tested
(Figure 2f). These speciﬁc immune response assays indicated that
CTLs reactive against TRP2 are present in peripheral blood mono-
nuclear cells of melanoma patients that can be activated in vitro with
SmartDC-TRP2, in an antigen-speciﬁc manner, to recognize and kill
melanoma.
Production of LV-G242T and SmartDC-TRP2 under GMP-compliant
conditions
We assessed the proof-of-concept feasibility of SmartDC-TRP2
production entirely under GMP-compliant conditions. We vali-
dated the upstream and downstream processes and established
standard-operating-protocols for the production of LV-G242T.
High-purity supercoiled plasmids were used for transfection of
293 T cells in layer ﬂasks (Figure 3a). After transfection, viral
supernatants were harvested and subjected to downstream
puriﬁcation (benzonase treatment, ﬁltration, chromatographic
puriﬁcation, centrifugation, ﬁlling and storage. The entire process
was performed in clean rooms). Total LV-G242T content was
determined by p24 ELISA for each processing step (Figure 4a). The
ﬁnal LV product corresponded to 148.5 μg p24 equivalent or 2.8 ×
109 infective units (determined by PCR). SmartDC-TRP2 production
under GMP-like compliant conditions (that is, outside the
clean rooms but with GMP-grade material) was subsequently
Table 1. Comparisons between in vitro assay analyses
Patient number IFN- γ ELISPOT after II stimulations CD8+ T-cell expansion after III
stimulations
TRP2360-368 tetramer (% tetramer
+ in
CD3+/CD8+ cells)
SmartDC SmartDC/pep SmartDC-TRP2 SmartDC SmartDC/pep SmartDC-TRP2 SmartDC SmartDC/pep SmartDC-TRP2
#1 14.0 94.0 60.0 9.7 14.0 14.5 0.1 0.2 0.3
#4 16.0 84.0 86.0 17.1 22.3 36.7 0.2 0.7 1.1
#9 40.0 105.0 105.0 18.0 33.3 40.9 NA NA NA
#22 63.0 103.0 145.0 8.4 32.1 25.2 NA NA NA
#50 6.0 54.0 35.0 10.4 18.4 22.5 1.0 0.6 0.7
Mean±s.e.m. 27.8±12.1 88.0±10.7 86.8±17.9 12.7±1.8 24.0±3.4 28.0±4.3 0.4±0.23 0.5±0.12 0.7±0.18
Fold change vs SmartDC — 3.2 3.1 — 1.9 2.2 — 1.2 1.8
Abbreviations: CTL, cytotoxic T lymphocyte; IFN-α, interferon-α; PBMNC, peripheral blood mononuclear cell; SmartDC, self-differentiated myeloid-derived
antigen-presenting-cells reactive against tumors-dendritic cell; TRP2, tyrosinase-related protein 2. SmartDC-TRP2 potency assays performed with PBMNCs
obtained from advanced melanoma patients. IFN-γ ELISPOT, T-cell expansion and CTL reactivity by tetramer (TRP2360-368) analyses obtained for melanoma
patients. Fold increase was calculated for SmartDCs expressing or loaded with the TRP2 antigen versus ‘empty’ SmartDC used for CTL expansion in vitro.
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performed. The leukapheresis product obtained from a HLA-
A*02:01 positive donor was transported under controlled condi-
tions to the GMP facility. The entire cell handling (leukapheresis,
CD14+ isolation, cytokine preconditioning, transduction, wash and
cryopreservation) was completed in a total of 3 days, from which
the gene transfer required 24 h of processing (Figure 3b). Quality
control analyses were included after each step of the process to
assess viable cell recovery (Figure 4a). SmartDC-TRP2 were
cryopreserved at a density of 2 × 106 ml− 1 per vial and were
maintained cryopreserved for at least 10 days prior to thaw and
ﬁnal quality control.
Characterization of the genetically modiﬁed cell product after
in vitro culture
Analytical methods were applied for independent triplicates in
order to demonstrate the consistent viability, morphology,
self-differentiation, expression of transgenic cytokines and endo-
genously upregulated cytokines after thawing and ex vivo culture.
Cryopreserved monocytes from the same CD14+ selection used for
SmartDC-TRP2 production were thawed and used as mock
controls. As an additional control group, monocytes were thawed
and ConvDCs were prepared in the research laboratory (culture
with GM-CSF and IL-4). After 7 days of culture, 36–48% and
30–38% recovery was obtained for SmartDC-TRP2 (maintained in
CellGro) and ConvDCs (maintained in CellGro plus cytokines)
relative to thawed input, respectively (Figure 4c). Thus, GM-CSF
and IL-4 gene transfer resulted in higher cell recovery on day 7
than culture with exogenous cytokine treatment, whereas only
11–14% of monocytes maintained in CellGro were recovered after
7 days (Figure 4c). SmartDC-TRP2 analyzed immediately after thaw
showed high viability (490% 7AADneg) and purity (490% CD45+
and CD14+ no T, B and natural killer cells; Figure 4d). After in vitro
Scheme of cytotoxicity assays
TRP2 expression in target cell linesc. FEMX-1/CFSE and cytotoxicity assay
Cytotoxicity against FEMX-ICytotoxicity against KA2/TRP2Cytotoxicity against KA2
Figure 2. Pre-clinical validation of SmartDC-TRP2 potency generated from melanoma patients. CTLs stimulated with SmartDC or SmartDC/pep
or SmartDC-TRP2 were analyzed for their ability to speciﬁcally lyse the target cells expressing TRP2. CTLs were co-cultured with TRP2
expressing KA2/TRP2 or FEMX-I cells at various effector to target (E:T) ratios and the cytotoxic ability was determined by CFSE-based assay.
(a) Scheme of cytotoxicity assays. (b) TRP2 expression in KA2, KA2/TRP2 and FEMX-I target cells analyzed by intracellular staining. Filled and
unﬁlled histograms indicate FACS analyses with isotype control or relevant mAbs; numbers indicate percentages of positive cells. (c) CFSE
staining of FEMX-I targets used in the cytotoxicity assays. CFSE staining of FEMX-I targets before co-culture with the effector cells in the
cytotoxicity assay and CFSE staining of FEMX-I targets after co-culture with CTL generated with SmartDC and CTL generated with SmartDC-
TRP2. The right peak in the histograms show the live CFSE+ targets after the cytotoxicity. Filled histogram in the ﬁrst panel indicates isotype
control for CFSE staining. (d–f) CFSE-based cytotoxicity assays. The line graph shows the percentage-speciﬁc lyses of T cells obtained from the
microcultures of melanoma patients (n= 3). The data represents the average of triplicate wells performed with cells obtained from
microcultures after three stimulations. (d) KA2 as targets, (e) KA2/TRP2 as targets and (f) FEMX-I as targets. T cells stimulated with SmartDC
without any antigen is shown in open circles; T cells stimulated with SmartDC-TRP2 are shown in black triangles. Error bars indicate mean±
s.e.m.; ***Po0.001, **Po0.01 and *Po0.05.
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culture, SmartDC-TRP2 showed typical DC morphology (Figure 4e)
and immune phenotypic features (downregulation of CD14;
high expression of DC markers CD209, CD86 and HLA-DR;
Figure 4f). Signiﬁcantly higher concentrations of GM-CSF
(17.7 pgml− 1), IL-4 (22.3 pgml− 1), monocyte chemoattractant
protein-I (1938.7 pgml− 1) and interleukin-8 (IL-8) (2707.1 pgml− 1)
were obtained for SmartDC-TRP2 than in monocyte culture
supernatants harvested on day 7 (Figures 4g and h).
Analyses of vector titer and genomic integration of LV sequences
in SmartDC-TRP2
DNA was isolated from SmartDC-TRP2 maintained in culture for
7 days and mock monocytes were used as baseline controls.
Detectable LV copies were obtained in transduced monocytes at
1.66 copies per cell (mock monocyte controls: 0.003 copies per
cell; Figure 5a). As LVs are actively being pursued in clinical trials,
risk concerns regarding insertional mutagenesis require compre-
hensive characterization of the product. Although DCs are
post-mitotic and non-replicating cells, a biased integration pattern
in a potentially oncogenic locus could predispose to insertional
mutagenesis and genotoxic effects. Therefore, LV integration
pattern in genomic DNA obtained from day 7 SmartDC-TRP2 was
analyzed by linear ampliﬁcation mediated-PCR (LAM-PCR) and
next-generation sequencing and the clonal frequencies were
monitored with a high-throughput integration site (IS) analysis.31
The number of total vector sequences that could be retrieved for
the SmartDC-TRP2 were in the order of 104, whereas after
applying the ﬁltering methods, the detectable number of unique
IS was 159 (46-fold reduction; Figure 5b). The integration pattern
was highly polyclonal and the 10 most frequent identiﬁed gene
loci were discordant and did not occur near oncogenes
(Figure 5c). LV integrations were not found in chromosome Y.
For all other chromosomes, integration frequencies were roughly
correlated with chromosome size (Figure 5c). As expected, LV
integrated sequences were found in higher frequency in genes
than in regions upstream of the transcription start site (Figure 5d).
Overall, these analyses conﬁrmed previous observations that LV
integrations are random showing a polyclonal non-biased
integration proﬁle not matching a known biased integration
sequences assigned for gamma-retroviral genotoxicity, such as
LMO2.32
Potency of GMP-grade SmartDC-TRP2
GMP-grade SmartDC-TRP2 cultured for 7 days were mixed with
autologous CD8+ T cells (DC 1: T cell 10 ratio) for up to three
consecutive stimulation rounds (Figure 6a). Research-grade
Figure 3. Standardized production of LV-G242T and SmartDC-TRP2 under GMP-compliant conditions: up-scaling and recovery. (a) Schematic
representation of pilot batch of the lentiviral vector production performed under GMP-compliant conditions. (b) Schematic ﬂow diagram
representing the production of one pilot batch of SmartDC-TRP2 generation under GMP-like conditions.
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‘empty’ SmartDC and SmartDC/pep generated from the same
CD14+ selection were used as negative and positive controls,
respectively. All co-cultures were set up in triplicates. Relative to
T-cell input, SmartDC-TRP2 stimulated the highest expansion of
T cells after three rounds of stimulations (20-fold), followed by
SmartDC/pep (10-fold) and SmartDC (5-fold) (Figure 6b). For IFN-γ
ELISPOT assay, T cells stimulated with DCs twice were co-cultured
with target KA2 or KA2/TRP2. Relative to T cells expanded with
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Figure 4. Characterization of SmartDC-TRP2 produced under GMP-compliant conditions. CD14+ monocyte selection was performed by
CliniMACS. 2 × 108 monocytes were transduced in bags with 1 × 109 infectious particles at an multiplicity of infection (MOI) of 5. Transduced
monocytes were washed and cryopreserved. SmartDC-TRP2 produced under GMP were thawed, cultured in vitro and analyzed on days 1, 3
and 7. Characterization was aimed at specifying markers of DC differentiation and potency. (a) LV-G242T recovery after each step of
production process. (b) CD14+ cell recovery as viable cell numbers after each step of production process and after thaw (extrapolated).
(c) Percentage recovery of viable cells (determined by trypan blue dye exclusion) on days 1, 3 and 7 after culture in medium without
exogenous addition of cytokines (n= 3). Line graph indicate average values obtained from three independent experiments. Error bars indicate
mean± s.e.m. *Po0.05. (d) Representative example of QC and batch release criteria for one GMP-like batch, showing high viability, purity and
expected monocyte characteristics of the product after thawing. (e) Phase microscopy of SmartDC-TRP2 showing typical DC morphology on
day 7 of in vitro culture, comparable to ConvDC cultured in the presence of cytokines. (f) Immunophenotypic analyses as percentage positive
and mean ﬂuorescent intensity (MFI). Histogram bars represent average values obtained from three independent experiments. Error bars
indicate mean± s.e.m. (g) Concentration of GM-CSF and IL-4 in cell supernatants harvested on day 7 after thaw (pgml− 1). (h) Concentration of
endogenously upregulated MCP-1 and IL-8 (pgml− 1). Data represents the average of three independent runs. Bar graphs indicate mean and
error bars indicate mean± s.e.m. **Po0.01; ***Po0.001.
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‘empty’ SmartDC, signiﬁcantly higher reactivity against KA2/TRP2
cells was observed for T cells stimulated with SmartDC-TRP2
(11-fold; ****Po0.0001) or with SmartDC/pep (3-fold; **Po0.01;
Figure 6c). CTLs expanded after three rounds of stimulation were
analyzed for their ability to lyse target cells using a lactate
dehydrogenase-based cytotoxicity assay. Expanded T cells showed
low reactivity (o5% lyses) against the negative control KA2
targets at different E:T ratios (Figure 6d). At the highest E:T ratio
(27:1), T cells stimulated with SmartDC-TRP2 or SmartDC/pep and
co-cultured with KA2/TRP2 cell resulted into ~ 30% cytotoxicity
(10- and 8-fold higher than CTLs expanded with SmartDC,
respectively (Figure 6e)). Thus, SmartDC-TRP2 produced under
GMP-compliant conditions expanded T cells capable to speciﬁcally
recognize and lyse TRP2-positive cell targets.
DISCUSSION
Several clinical and preclinical studies have pointed out that the
optimal approach to control recurrent melanoma will likely be
a combination of de-bulking strategies (surgery and systemic
therapies) with adjuvant immune modulators and personalized
immune therapy approaches. The current work results from
further translational developments of the SmartDC technology
previously tested with murine SmartDC derived from bone
marrow unfractionated cells in vivo using the B16 melanoma
model transplantable to C57BL/6 mice. We have previously shown
in several publications that SmartDC-TRP2 consistently resulted
into expansion of TRP2-speciﬁc CD8+ T cells that induced B16
tumor protection or regression.26,27,29 Mouse SmartDC were more
viable (2–3 weeks) than ConvDCs produced with recombinant
cytokines and actively migrated to adjacent inguinal lymph nodes.
Other than sporadic vitiligo and alopecia, probably mediated due
to abrogated immune tolerance for skin and hair follicle cells
producing melanin, no other toxicities or malignancies were
observed in mice maintained long term. Concurrently, we have
also previously shown that human cryopreserved/thawed
SmartDC-TRP2 marked with ﬁreﬂy luciferase were viable for
3–4 weeks after subcutaneous injection in Nod.Rag1− /−.IL2rγ− /−
mice with no toxic effects. Thus, these preclinical relevant in vivo
models demonstrated efﬁcacy and safety of SmartDC-TRP2 in
stimulation of TRP2-speciﬁc CTLs.
We demonstrated previously that mouse SmartDC-TRP2
injected subcutaneously into C57BL/6 mice after a lethal B16
melanoma challenge signiﬁcantly controlled tumor growth and
delayed death, but long-term survivors were rare.26,27,29 This could
be explained by the explosive and immune suppressive behavior
Unique Integrations
LV integrations in Chromosomes
IDLV copies/cell (day 7)
Distribution in gene and up stream
Most predominant insertions
Figure 5. Characterization of LV-G242T and integration site analyses in SmartDC-TRP2. (a) Transduced monocytes were thawed and cultured
in vitro for 7 days without exogenous addition of cytokines. On day 7, cells were harvested and analyzed by RT-q-PCR and integrated LV copy
numbers were determined (expressed as LV copies per cell). Monocytes were used as controls. (b) Total matched sequences and unique
integration sites (IS) analyses performed after LAM-PCR with the tDNA extracted from SmartDC-TRP2 (day 7) followed by NGS. Fold reduction
from the total matched sequences to IS is indicated. (c) 10 most predominant clones in SmartDC-TRP2. Colored columns represent retrieval
frequency as percentage of total sequences. Larger colored bars represent higher frequencies of integration sites clustering in the proximity
of that gene. Lower panel: ranking of the 10 most predominant clones with their corresponding color code and gene ID. (d) Frequency of
integrations per chromosome for the lot of GMP-compliant SmartDC-TRP2. (e) Distribution of integrations upstream of transcription start sites
(TSS; arrow) or in genes for research GMP-compliant batch of SmartDC-TRP2.
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of the B16 melanoma model once it takes hold. Nevertheless, we
observed in these studies, that the local LN became greatly
enlarged, resulting in a massive accumulation of host DC and
TRP2-reactive lymphocytes. High frequencies of CTL reactive
against TRP2 were detectable in spleen and LN as measured by
intracellular IFN-γ assays.29 Here, we corroborate the ﬁndings with
the human in vitro assays studies, showing that SmartDC-TRP2
generated from ﬁve advanced melanoma patients were highly
potent in expanding CTL memory cells and inducing TRP2-speciﬁc
lytic responses.
TRP2 (also known as dopachrome tautomerase) is a highly
conserved trans-membrane enzyme involved in tyrosine meta-
bolism, metabolic pathways and in melanogenesis.33 TRP2 is
expressed in normal (retina, melanocytes), pre-malignant tissues
(nevi) and tumors (melanocytic or amelanocytic melanoma,
retinoblastomas and glioblastomas). Melanoma cells show higher
TRP2 expression than normal melanocytes, and TRP2 function has
been linked with resistance of melanoma cells to chemotherapy
and radiation treatments.33 T-cell and humoral reactivity against
TRP2 could be demonstrated in healthy and cancer patients,
demonstrating that central tolerance for this antigen is not full,
that is, TRP2-reactive T cells are not depleted from the repertoire
and memory cells persist for immune surveillance.34–36 This agrees
with experimental systems such as transgenic mice developing
disseminated melanoma showing high frequencies of effector
memory CD8+ T cells reactive against TRP2 at the phase of
microscopic tumor load in lymph nodes.37 In another transgenic
mouse model recapitulating spontaneous melanoma, TRP2 has
been used as a marker for assessing melanoma spread,
remarkably revealing that melanoma disseminated in LN showed
Figure 6. Characterization of SmartDC-TRP2 potency produced under GMP-compliant conditions. SmartDC-TRP2 thawed and cultured in vitro
for 7 days were used in stimulation of autologous CD8+ T cells. SmartDC and SmartDC loaded with TRP2 peptide mix were used as controls.
CTLs were harvested after 7 days of co-culture with respective SmartDC groups and analyzed. Three rounds of stimulations were performed.
(a) Scheme of T-cell stimulation, expansion and analyses. (b) Relative fold expansion of T cells per group determined with trypan blue
exclusion staining (relative to T-cell input). Line graph indicate the average values of independent experiments and error bars indicate
mean± s.e.m. (c) IFN-γ ELISPOT analyses after two stimulations. 50 000 CD8+ T cells were co-cultured in the presence of KA2 cells or KA2 cells
endogenously expressing TRP2 (KA2/TRP2) on IFN-γ ELISPOT plates. Non-stimulated T cells were used as controls. Average number of spots
from duplicate wells was quantiﬁed. Histograms represent average number of spots from pooled microculture wells (n= 3) per experimental
condition. Bar graphs indicate average values of experiments performed and error bars indicate mean± s.e.m. ****Po0.0001 and **Po0.01.
(d and e) Cytotoxicity assay based on LDH. T cells stimulated with SmartDC-TRP2 were co-cultured with (d) KA2 or (e) KA2/TRP2 targets at
various effector to target (E:T) ratios. 8 h after the incubation, target cell lysis was determined by quantifying the LDH release in the respective
wells. SmartDC and SmartDC loaded with TRP2 pepmix (SmartDC/pep) were used as controls. Percentage cytotoxicity was calculated by the
following formula: % Cytotoxicity= (Experimental release-Effector spontaneous-Target spontaneous/Target maximum-Target spontaneous)
× 100. Line graph indicate the values quantiﬁed from triplicate wells.
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upregulation of TRP2 expression.38 Incidentally, TRP2 mRNA can
also be detected by quantitative PCR in tumor lesions and sentinel
LN of metastatic melanoma patients, demonstrating that the
antigen expression in tumor cells is not downregulated in these
key tissues, potentially enabling their recognition by CTLs.39,40
Surprisingly, despite vast experimental and clinical evidence
showing that non-mutated TRP2 is immunogenic, that TRP2
expression is maintained in melanoma spreading to LN and that
TRP2-speciﬁc CTLs can be quite potent at eliminating melanoma,
adoptive or adaptive immune therapies targeting TRP2 have not
been explored clinically.
The understanding of the tumor/host interaction is unraveling
with the clinical success and pitfalls of checkpoint blockers such as
PD-1. One interesting proposed counter-acting mechanism to this
therapy is the tumor adaptive immune resistance (that is, PD-L1
upregulation) in response to antigen-speciﬁc T-cell inﬁltration into
melanoma tumors.41 Quantiﬁcation of CTL inﬁltrates in tumors or
CTL expansion in sentinel LN are proposed to have predictive
value with respect to tumor regression.41 Therefore, if SmartDC-
TRP2 can induce a broad and effective type-I IFN inﬂammatory
CTLs able to accumulate in melanoma and LN metastases, the
combination of this vaccine with PD-1 blockade will merit clinical
investigation.
The ﬁeld of melanoma immune therapy has recently focused on
the discovery of class I-restricted neo-antigens, such that a highly
personalized antigenic or adoptive CTL treatment could be
administered. Yet, recognition of neo-antigens that arise due to
mutations in melanoma by CD4+ cells seems to be more frequent
and relevant than previously anticipated.42 Thus, presentation of
the full-length TRP2 antigen by SmartDC-TRP2 can activate both
CTL and helper responses. This could be ideally combined with
immunization with peptides encompassing class I- and class II-
restricted neo-antigens. This way, melanoma growth could be
combated immunologically in two fronts: as a ﬁrst multipotent
and broad immunologic hit against the over-expressed self-
antigen TRP2 in order to enhance type-I interferon inﬂammation
in tumor and LN, and a second immunologic hit, speciﬁcally
against mutated neo-antigens.
For these reasons, advancing toward innovative translational
combinations of immune therapies is currently warranted to
progress toward the next therapeutic level. At the same time,
cellular or viral vaccines will require simple and consistent
production method to facilitate multiple vaccination cycles and
large clinical trials to answer questions of efﬁcacy. Emphasizing
these requirements, in this study we demonstrated that LV-G242T
was readily successfully produced and puriﬁed in an academic
GMP manufacturing facility. These data demonstrated that our LV
production is comparable with the production methods that are
now currently being used by biotech companies for use in clinical
trials.43,44 In addition, feasibility of the entire production and
cryopreservation of the individualized SmartDC-TRP2 vaccine
under GMP conditions was achieved in only 3 days. About 25%
of the monocytes were recovered after transduction, wash,
cryopreservation and thawing. Previous studies with conventional
DC vaccines reported typically the use of 4 × 106 to 1 × 107 cells for
vaccinations in order to induce relevant immune responses.14,45,46
Thus, starting with 2.0 × 108 cells used for transduction, 5 × 107
viable cells after thawing would be enough to complete quality
control requirements and to be used in prime/boost immun-
izations combined with checkpoint blockade therapies. The
European Medical Agency requires rigorous characterization of
the cell product prior to administration into patients. Therefore,
SmartDC-TRP2 after thawing and in vitro culture were subjected to
analyses of identity, potency and effects of gene transfer.
Immediately after thawing, SmartDC-TRP2 corresponded to
490% pure CD14+ monocytes, conforming to the identity of
the cell type used for genetic manipulation. After 7 days of in vitro
culture, SmartDC-TRP2 differentiated autonomously into a uniform
cell lineage displaying typical DC immunophenotypic markers. In
agreement to our previous studies not conducted entirely under
GMP but using similar methods, we detected approximately two
LV copies per cell demonstrating comparable levels of gene
transfer.27 Detectable secretion of GM-CSF and IL-4 and two
upregulated chemokines (monocyte chemoattractant protein-I
and IL-8), which are all associated with DC differentiation/
maturation/activation can be again attributed to speciﬁcations
of SmartDC-TRP2 potency.27 Thawed SmartDC-TRP2 cultured
in vitro for 7 days stimulated autologous CTLs that could recognize
and kill cell targets loaded with TRP2 antigens on the cell surface
or expressing TRP2 endogenously.
One important concern for the ex vivo LV-based gene transfer is
still safety. Although LVs were shown to be safe in clinical trials
exploring gene transfer into hematopoietic stem cells and T
cells,25,43,47 monocytes genetically modiﬁed with LVs were never
used clinically and there is a concern regarding insertional
mutagenesis leading to myeloid malignancies. We therefore
investigated the LV integration pattern in SmartDC-TRP2 by
high-throughput IS analyses. Compared with the total sequences
retrieved by the method, unique ISs in identiﬁable loci were
reduced by 46-fold, possibly indicating a bottle-neck or integra-
tions in previously non-annotated loci. As a hallmark of LV
integration pattern, polyclonal integrated sequences were found
downstream the transcription start site. The 10 most predominant
clones did not show an integration bias for oncogenic loci. These
results provide optimistic implications for the SmartDC-TRP2 cell
vaccine and, further down, for a direct lentiviral vaccine bypassing
ex vivo cell manipulations.
Incidentally, in parallel with the development of SmartDC-TRP2
for melanoma immunotherapy in the autologous setting, in recent
years, our laboratory developed another type of engineered DC
for use in the allogeneic transplantation setting. The target
population are in this case immune-compromised cancer patients
after allogeneic hematopoietic stem cell transplantation. The
novel vaccine aspect is to accelerate the de novo donor-derived
adaptive immune responses and protect the recipient against
human cytomegalovirus (CMV). The vaccine consists of monocytes
reprogrammed ex vivo with a tricistronic self-inactivating integrase
defective LV (expressing GM-CSF, IFN-α and CMV-pp65 tegument
protein) to allow direct generation of Self-differentiated
Myeloid-derived Lentivirus-induced Dendritic Cells expressing
pp65 (SmyleDCpp65). Our benchmark was to validate monocytes
reprogrammed with integrase defective LV that self-differentiated
into SmyleDCpp65 in vitro and in vivo.48,49 SmyleDCpp65
promoted and accelerated de novo immune reconstitution of
functional effector T and mature plasma B cells after CD34+
peripheral blood hematopoietic stem cell transplantation in
humanized NOD/Rag1null/IL2Rγnull (NRG) mice.55 Remarkably,
SmyleDCpp65 stimulated lymph node regeneration, thymopoiesis,
human pp65-speciﬁc T-cell immunity and human antibody
responses (immunoglobulin M and immunoglobulin G) in
lymphopenic NRG transplanted mice. Xenograft Graft-versus-Host
Disease (GvHD) was absent or mild, and no safety concerns were
observed in this relevant animal model. Efﬁcacy of cryopreserved/
thawed SmyleDCpp65 was also established by extensive testing
of pharmacodynamic activity in humanized mouse models.
Feasibility of both integrase defective LV (ID-LV) production and
GMP-compliant cell manufacturing were completed with a
contract manufacturing organization (EUFETS GmbH, Germany;
Sundarasetty et al., submitted). Integrase defective LV are
particularly attractive as their integration in the host genome is
dramatically diminished (estimated to be 1000-fold), and thus
resulting in lower risks of insertional mutagenesis.50 Therefore, a
next logical step to improve the SmartDC-TRP2 or lentiviral
vaccine safety proﬁle, will be to employ ID-LVs. Upon transduction
of target cells, the default pathway of virus integration is changed
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into accumulation of episomal circular viral genomes, whereby
transgene expression still persists in differentiated DCs.
Ultimately, the future of lentivirus-reprogramming DCs per-
formed ex vivo or in vivo is promising, as the cytokines and
antigens used in the LV can be exchanged to suit the disease. This
new methodology could modernize and transform the ﬁeld of
cancer vaccines. The method can potentially be entirely auto-
matized for multicentric trials to answer questions of efﬁcacy,
aimed to promote multipotent cellular protection against speciﬁc
antigens. The technology is modular and the applicability of this
cell vaccine against cancer is broad, including further genetic
engineering developments of the cell product as actively
personalized vaccines, that is, by co-expression of tumor-speciﬁc
neo-antigens.
MATERIALS AND METHODS
Cell lines
The HEK-293 (human embryonic kidney-293) cell line encoding the simian
virus 40 large T antigen (heretofore, 293 T cells) was used for the
production and characterization of LVs (both research grade and GMP
grade). A fully characterized 293 T-based master cell bank was established
at Cell and Gene Therapy at King’s (King’s College London, London, UK).
FEMX-I (human malignant melanoma HLA-A*02:01 positive cell line,
originating from a lymph node metastasis in a patient, kindly provided
by Professor Dr. Udo Schumacher University Clinic Hamburg-Eppendorf)
was used as targets in cytotoxicity assays. 293 T cells and FEMX-I cells were
cultured at 37 °C and 5% CO2 in Dulbecco’s modiﬁed Eagle’s medium
(Invitrogen, Darmstadt, Germany) supplemented with 10% fetal bovine
serum (HyClone, Bonn, Germany). K562 cells expressing HLA-A*02:01 (KA2
cells, kindly provided by Professor Dr. Thomas Woelfel, University Clinic
Mainz) were transduced for TRP2 expression (KA2/TRP2) and cultured in
RPMI supplemented with 10% fetal bovine serum, 1% Penicillin/
Streptomycin and 1mgml− 1 Geneticin (Biochrom AG, Berlin, Germany).
LVs and plasmids
LV-G24 (expressing human GM-CSF (hGM-CSF) and human IL-4) and LV-
G242T (expressing, in addition, TRP2) were constructed and produced as
described.27,28 LV-G242T was produced under GMP conditions following
standard operation procedure established at Cell and Gene Therapy at
King’s, King’s College London. All packaging plasmids were fully
sequenced and produced by PlasmidFactory GmbH (Bielefeld, Germany)
as ccc-supercoiled plasmids, enzyme free and devoid of animal-derived
materials and certiﬁed for purity. On day 0, multi-layer culture ﬂasks were
seeded with 293 T cells and cultured to sub-conﬂuent optimal density in
Dulbecco’s modiﬁed Eagle’s medium. CaPO4 transfection was performed
with the transfer plasmid and the packaging plasmids. 24 h after
transfection, medium change and Benzonase treatment were performed.
Supernatant containing virus was harvested at 24 h (harvest I) and 48 h
(harvest II). The virus supernatant was ﬁrst clariﬁed through 0.45 μm
ﬁlters and processed by anion exchange chromatography (CEX) using
a MustangQ XT5 capsule (Pall). The column was sterilized with NaOH, and
equilibrated with NaCl and Tris pH 8.0. Virus supernatant was adjusted to a
ﬁnal equimolar concentration of NaCl and Tris pH 8.0 and passed through
the column. Virus particles were then eluted in increased NaCl/Tris pH 8.0
followed by phosphate-buffered saline (PBS). The eluate containing virus
was then further diluted in PBS and subjected to centrifugation. After
centrifugation, the virus was resuspended in CellGro medium (CellGenix,
Freiburg, Germany). A 250-fold volume reduction was achieved from bulk
harvest to ﬁnal concentration. The CellGro formulated ﬁnal concentrated
virus suspension was ﬁlled in 1ml per vial aliquots and stored at − 80 °C.
Titration of integrase defective LV-G2α2pp65 by p24 analyses
Physical titers of the vectors produced (research grade and GMP grade)
were determined by quantifying the p24 HIV-I core protein by ELISA
(QuickTiter HIV Lentivirus Quantitation Kit, BioCat, Heidelberg, Germany).
Titration of the vector and analyses of vector copy numbers in
monocytes by RT-q-PCR
For virus titration, 293 T cells were transduced and genomic DNA was
extracted from using the QiaAmp DNA blood mini kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. LV copy numbers
were determined by real-time PCR as previously described.49,51 Brieﬂy, 2 μl
containing 100 ng of genomic DNA were added to 13 μl of RT-q-PCR mix
(containing 7.5 μl of SYBRTaq mix with 1 μl of wPRE/PTB2 primer mix (wPRE
forward: 5ʹ-GAGGAGTTGTGGCCCGTTGT-3ʹ, wPRE reverse: 5ʹ-TGACAGGTG
GTGGCAATGCC-3ʹ or PTBP2 (polypyrimidine tract binding protein
2; PTBP2 forward: 5ʹ-TCTCCATTCCCTATGTTCATGC-3ʹ, PTBP2 reverse: 5ʹ-
GTTCCCGCAGAATGGTGAGGTG-3ʹ) and 4.5 μl PCR grade, nuclease free
water). All samples were analyzed with StepOnePlus Real time PCR system
(Applied Biosystems, Life Technologies, Darmstadt, Germany). The cycling
conditions were 10min at 95 °C, 40 cycles of 15 s at 95 °C, 20 s at 56 °C and
30 s at 65 °C. Results were quantiﬁed by making use of primer pair-speciﬁc
real-time PCR efﬁciencies and by comparing sample CT values with a
standard curve generated with the plasmid vector (pCR4-TOPO) containing
the wPRE and PTB2 sequences. Data was analyzed by StepOnePlus
software (Applied Biosystems).
SmartDC-TRP2 generation from melanoma patients
Peripheral blood mononuclear cells were obtained as leukapheresis from
melanoma patients in accordance with study protocols approved by
Hannover Medical School Ethics Review Board. After informed consent, 50
cc peripheral blood mononuclear cell were collected at diagnosis from a
total of 50 patients with melanoma stage III and IV. As some of our immune
assays required antigen presentation through HLA-A*02:01, HLA typing
was performed and we identiﬁed 20 patients. After a second informed
consent, ﬁve HLA-A*02:01 melanoma patients (stage III and IV) who had
reached remission and were stable were asked to donate additional
leukapheresis material for more extensive immunologic assays, requiring
large numbers of T cells. Tumor samples from three patients were
conﬁrmed to be positive for TRP2 expression by PCR.52 SmartDC-TRP2 were
generated from CD14+ monocytes obtained from melanoma patients as
previously described.27 CD14+ monocytes were isolated by immunomag-
netic positive selection, (Miltenyi Biotec, Bergisch Gladbach, Germany)
preconditioned with hGM-CSF and human IL-4 (50 ngml− 1 each,
CellGenix) for 8 h. 2.5 μgml− 1 p24 equivalent of LV-G24 or LV-G242T
were used to transduce 5 × 106 monocytes at multiplicity of infection
(MOI) of 5 in the presence of 5 μgml− 1 protamine sulfate (Valeant,
Eschborn, Germany) for 16 h. After transduction, cells were washed twice
with CellGro medium (CellGenix). Conventional DCs (ConvDCs) were
generated from monocytes by supplementing the medium with hGM-CSF
and human IL-4 every 3 days.
Flow cytometry analyses of DCs
We used the following monoclonal antibodies reactive against DC markers:
CD86-PE, HLA-DR-PerCP, CD80-PE, CCR2-AlexaFlour 647, CCR5-PerCP
(Becton Dickinson, Heidelberg, Germany) and respective monoclonal
antibody isotype controls. Cells were collected, washed once with PBS,
blocked with PBS containing mouse IgG (50 μgml− 1) incubated on ice for
15min and stained with the corresponding monoclonal antibodies for
30min. Cells were washed and resuspended in cell-ﬁx solution (Becton
Dickinson). Cells were then analyzed using a FACSCalibur cytometer
(Becton Dickinson). Acquisition was performed using CellQuest software
and analyses were performed using Flowjo software (Treestar Inc., Ashland,
OR, USA).
Functional analyses of TRP2-speciﬁc T-cell responses in melanoma
patients
SmartDC and SmartDC-TRP2 generated with peripheral blood mono-
nuclear cells of melanoma patients were harvested 7 days after
transduction and used directly for the ﬁrst T-cell stimulations or
cryopreserved for subsequent re-stimulations. Autologous CD8+ T cells
were selected from the CD14− fraction by magnetic bead isolation
(Miltenyi Biotec). T cells and DCs were seeded at a 10:1 ratio (T:DC).
Autologous feeder cells (CD14− /CD8−) were gamma-irradiated with 40 Gy
(Gammacell 3000 Elan, Best Theratronics Ltd., Ottawa, ON, Canada) and
added to the co-cultures. Co-cultures were maintained for 7 days in
X-VIVO-15 (Lonza, Köln, Germany) containing 5% human AB serum (Lonza,
Basel, Switzerland) and cytokines IL-2: 25 infective unit per ml (Novartis
GMP-compliant LV-induced DCs for melanoma immunotherapy
BS Sundarasetty et al
717
© 2015 Macmillan Publishers Limited Gene Therapy (2015) 707 – 720
Pharma GmbH, Nürnberg, Germany), IL-7: 5 ngml− 1 and IL-15: 5 ngml− 1
(CellGenix). The medium with cytokines was replenished every 2 days.
Re-stimulations were performed after every 7 days by adding the
corresponding numbers of cryopreserved/thawed DCs, to the T cells at a
ratio of T:DC of 10:1. Expanded T cells were analyzed by IFN-γ ELISPOT
assay. 30 000 expanded T cells were harvested and seeded per well on IFN-
γ antibody-coated ELISPOT plate and incubated overnight with KA2 cells,
KA2 cells loaded with TRP2 overlapping peptide pool (KA2/peptide) or KA2
cells endogenously expressing TRP2 (KA2/TRP2). The plates were devel-
oped as described by the manufacturer (Mabtech, Nacka Strand, Sweden)
and analyzed using ImmunoSpot Analyzer (CTL-Europe GmbH, Bonn,
Germany).
Tetramer analysis of TRP2-reactive T cells
T cells expanded in vitro were stained with TRP2-speciﬁc tetramers:
HLA-A*02:01-SVYDFFVWL-PE (TRP2180-188) or HLA-A*02:01-TLDSQVMSL-APC
(TRP2360-368) produced at the Ludwig Institute for Cancer Research,
Lausanne, Switzerland (kindly provided by Dr. Philippe Guillaume and Prof.
Immanuel F. Luescher). An PE-conjugated irrelevant tetramer was used as
negative control (Beckman Coulter, Krefeld, Germany). 2 × 105 stimulated
T cells were incubated for 30min at room temperature with tetramer,
washed once, stained with surface antibodies (CD8-FITC, CD3-PECy7, BD
Biosciences, Heidelberg, Germany) for 20min at 4 °C, washed once,
ﬁxed and analyzed in a LSR II ﬂow cytometer (BD Biosciences). At least
10 000 CD3+/CD8+ viable cells were analyzed. Tetramer-positive cells were
expressed as the percentage of total CD3+/CD8+ T cells.
Carboxyﬂuorescein diacetate succinimidyl ester-based cytotoxicity
analyses
Carboxyﬂuorescein diacetate succinimidyl ester (CFSE)-based cytotoxicity
analyses were performed as described.53 KA2/TRP2 or FEMX-I cells
were washed with PBS, resuspended at 1 × 107 cells ml− 1, labeled
with 10 μM CFSE (Sigma-Aldrich, Schnelldorf, Germany) for 10min at
37 °C, washed and resuspended in X-VIVO-15 (Lonza) at 5 × 106 cells ml− 1.
The T cells expanded with SmartDC or SmartDC-TRP2 cultures were
harvested, washed and resuspended in X-VIVO-15 (Lonza) at 5×104
cells ml−1. T cells and KA2/TRP2/CFSE or FEMX-I/CFSE targets were mixed in
various E:T ratios and incubated at 37 °C and 5% CO2 for 8 h. After co-
culture, T cells were labeled with ﬂuorochrome-conjugated antibodies
(CD8-PE-Cy7 and CD3-APC; BD Biosciences). Fluorochrome-labeled
microbeads were added to facilitate the quantiﬁcation of the CD3−/
CD8−/CFSE+ not lysed melanoma cells by ﬂow cytometry. The percentage-
speciﬁc lysis was calculated by the following formula: % speciﬁc
lysis = 100− (CD8−CFSE+ live target cells in the test sample/CD8−CFSE+
live target cells in the control sample with no T cells) × 100. The acquisition
was carried out in FACS LSR II (BD Biosciences) and the results were
analyzed using Flowjo software v. 7.6.4 (Treestar Inc.).
SmartDC-TRP2 production under GMP-compliant conditions
After informed consent, leukapheresis was obtained from healthy adult
volunteers (HLA-A*02:01) with a COBE Spectra apheresis system. CD14+
monocytes were enriched by immunomagnetic separation using a GMP-
compliant CliniMACS system (Miltenyi Biotec). Quantitative and qualitative
analyses of the selected CD14+ fraction and ﬂow through were performed
by ﬂow cytometry. From the enriched CD14+ fraction, 2 × 108 cells were
resuspended in 25ml of serum-free CellGro DC medium (CellGenix) and
seeded in a 100ml bag (CellGenix). Cells were preconditioned with 25ml
of medium containing hGM-CSF and human IL-4 cytokines (50 ngml− 1
each, CellGenix) for 8 h. Cells were transduced with 1 × 109 infective
particles (multiplicity of infection of 5) in 50ml medium containing
Protamine sulfate (5 μgml− 1). The bag was incubated at 37 °C and 5% CO2
for 16 h. Next day, cells were washed three times with CellGro medium.
After washing, cell number and viability was determined. Transduced cells
were cryopreserved in aliquots of 2 × 106 cell ml− 1 per vial. Surplus, non-
transduced monocytes were cryopreserved in aliquots of 2 × 106 cell ml− 1
per vial and 50× 106 cell ml− 1 per vial and were used as controls for the
characterization experiments. Sterility tests were performed with the
‘Bactec’ system (BD Biosciences).
Analyses of thawed GMP-grade SmartDC-TRP2 by ﬂow cytometry
analyses
Monocytes transduced with LV-G242T were seeded at a concentration of
1x106 cells ml− 1 in CellGro and analyzed after 1, 3 or 7 days of in vitro
culture. Surface marker expression was analyzed by ﬂow cytometry using
the following monoclonal antibody conjugated with ﬂuorochromes:
CD209-FITC, CD14-PE, HLA-DR-PerCP and CD86-APC (BD Biosciences).
Non-transduced monocytes were used as negative controls and conven-
tional DCs (ConvDCs) were used as positive controls. Acquisitions and
analyses were performed by LSR II and Flowjo analyses software.
Analyses of cytokines and transgene expression
Cytokines accumulated in SmartDC-TRP2 culture supernatants were
analyzed by multiplex luminex based kit according to the manufacturer’s
protocol (Milliplex Millipore, MA, USA).
Analyses of GMP-grade SmartDC-TRP2 potency by T-cell
stimulation in vitro
CD3+ T cells autologous to DCs were isolated from the CD14− fraction by
magnetic-activated cell sorting-positive selection (MACS, Miltenyi Biotec).
IFN-γ ELISPOT with the stimulated T cells was performed as described
above. Non-radioactive and colorimetric based cytotoxicity assays were
performed with CytoTox 96 non-radioactive cytotoxicity assay (Promega,
Mannheim, Germany) according to the manufacturer’s protocol. CD8+
T cells were stimulated with SmartDC or SmartDC/pep or SmartDC-TRP2
and subsequently were co-cultured with 10 000 KA2/TRP2 cells per well at
various E:T ratios. Target cell lysis was measured by quantifying lactate
dehydrogenase release into the medium in an enzymatic coupled assay.
Percentage cytotoxicity was calculated by the following formula: %
Cytotoxicity = (Experimental release− Effector spontaneous− Target spon-
taneous/Target maximum− Target spontaneous) × 100. Graphs depict the
values quantiﬁed from triplicate wells.
Integration analyses by next-generation sequencing
Integration analyses were performed using LAM-PCR to identify the LV-
ﬂanking genomic sequences as described.31 Brieﬂy, total DNA was
extracted from the samples after 7 days in culture as described.54 Two
50-cycle linear PCR ampliﬁcation steps were carried out using biotinylated
primers hybridizing to the 3-prime region of the long-terminal repeats of
the vector. The biotinylated PCR products were further captured with
paramagnetic beads followed by second strand DNA synthesis, restriction
digestion and ligation of a cohesive double-stranded linker sequence
carrying a molecular barcode of 12 nucleotides. Two nested PCR were then
performed with linker- and vector-speciﬁc primers each complementary to
one of the known ends of the target DNA. In 5ʹ–3ʹ orientation, LAM-PCR
products contained a long-terminal repeat sequence, a ﬂanking human
genomic sequence and a linker cassette sequence. LAM-PCR amplicons
were further prepared for MiSeq sequencing (Illumina, San Diego, CA,
USA). Therefore, an additional PCR with special fusion primers carrying
MiSeq-speciﬁc sequencing adapters was performed. DNA barcoding was
used to allow parallel sequencing of multiple samples in a single
sequencing run. Libraries were mixed with an φX bacteriophage genome
library to introduce diversity and optimize the sequencing run perfor-
mance and sequenced using the Illumina MiSeq v2 Reagent Kit. The pair-
end runs were initiated for Illunima’s sequencing by synthesis technology,
including clustering, paired-end preparation, barcode sequencing and
analysis. After completion of the run, base calling was performed on data,
sequences were de-multiplexed and φX reads were ﬁltered. Next-
generation sequencing data processing dealt with the management of
high-throughput data from Roche 454/Illumina MiSeq sequencing plat-
forms and comprise two main goals: (1) data quality inspection and
analysis, in which LV sequences and other contaminants were trimmed; (2)
integration site identiﬁcation, in which all valid sequence reads are aligned
to the genome of reference and valid ISs were retrieved.
Statistical analysis
Student’s t-tests and Bonferroni post-tests were performed for the data
derived using the GraphPad Prism software (GraphPad Software Inc., La
Jolla, CA, USA). All tests were two-sided and the P-values o0.05 were
considered signiﬁcant and were indicated.
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